Related Experiment Video

Updated: Aug 8, 2026

A Novel Surgical Approach for Intratracheal Administration of Bioactive Agents in a Fetal Mouse Model
10:12

A Novel Surgical Approach for Intratracheal Administration of Bioactive Agents in a Fetal Mouse Model

Published on: October 31, 2012

Prevention and treatment of fetal lung immaturity

E V Cosmi1, G C Di Renzo

  • 1Institute of Gynecology and Obstetrics, University of Perugia, Italy.

Fetal Therapy
|January 1, 1989
PubMed

Insights

Glucocorticoids (GC) reduce neonatal respiratory distress syndrome (RDS) in premature infants. Ambroxol also shows promise, while inositol may mitigate GC side effects, improving fetal lung maturity.

Area of Science:

  • Neonatal Medicine
  • Pharmacology
  • Obstetrics

Background:

  • Neonatal respiratory distress syndrome (RDS) remains a significant concern in premature infants.
  • Current prevention strategies focus on accelerating fetal lung maturity and developing surfactant treatments.
  • Glucocorticoids (GC) are the most studied drugs for antenatal administration to promote lung development.

Purpose of the Study:

  • To review strategies for preventing neonatal respiratory distress syndrome (RDS).
  • To evaluate alternative drugs like ambroxol and aminophylline for accelerating fetal lung maturity.
  • To assess the combined effects of glucocorticoids (GC) with inositol and the role of surfactant therapy.

Main Methods:

  • Review of existing literature on antenatal therapies for RDS prevention.
  • Analysis of experimental studies on ambroxol, aminophylline, and inositol.
  • Evaluation of clinical data on surfactant replacement therapy.

Main Results:

  • Glucocorticoids (GC) are effective in reducing RDS incidence in specific premature infant groups (28-32 weeks, <1500g).
  • Ambroxol demonstrated significant RDS reduction versus placebo with minimal adverse effects.
  • Inositol mitigated adverse effects of GC, improving fetal lung mechanics; aminophylline showed limited benefit; surfactant therapy improved oxygenation in premature infants.

Conclusions:

  • Antenatal therapies, including glucocorticoids (GC) and newer agents like ambroxol, are crucial for preventing neonatal respiratory distress syndrome (RDS).
  • Inositol may enhance GC efficacy and reduce side effects, while surfactant replacement therapy is vital for treating established RDS.
  • Continued research into optimizing drug delivery and combination therapies is essential for improving outcomes in premature neonates.

More Related Videos

Continuous Telemetric In Utero Tracheal Pressure Measurements in Fetal Lambs05:40

Continuous Telemetric In Utero Tracheal Pressure Measurements in Fetal Lambs

Published on: December 22, 2023

Development of a Neonatal Piglet Acute Lung Injury Model Recreating the Early Environment of Preterm Infant Lungs08:58

Development of a Neonatal Piglet Acute Lung Injury Model Recreating the Early Environment of Preterm Infant Lungs

Published on: October 31, 2025

Related Concept Videos

Breathing01:05

Breathing

The process of breathing, inhaling and exhaling, involves the coordinated movement of the chest wall, the lungs, and the muscles that move them. Two muscle groups with important roles in breathing are the diaphragm, located directly below the lungs, and the intercostal muscles, which lie between the ribs. When the diaphragm contracts, it moves downward, increasing the volume of the thoracic cavity and creating more room for the lungs to expand. When the intercostal muscles contract, the ribs...
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Pulmonary Cycle: Exhalation01:17

Pulmonary Cycle: Exhalation

In terms of human respiration, the act of expelling air, known as exhalation (or expiration), operates on the principle of pressure gradients. During expiration, the pressure within the lungs exceeds that of the surrounding atmosphere. Under normal conditions, quiet breathing involves passive exhalation and is free of muscular contractions. This is because the exhalation process is driven by the natural elastic recoil of the lungs and chest wall, both of which have an inherent tendency to...
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
Acute Respiratory Failure-V01:29

Acute Respiratory Failure-V

The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...